Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study

NCT ID: NCT06024837

Last Updated: 2024-09-20

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-06-07
• Study Completion Date: 2025-06-30

Brief Summary

Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.

Detailed Description

First of all, the virtual creation of mono-energy images between 40 and 140 keV has shown subjective and objective improvement of tumor detection of hypovascular lesions using low energies (40keV). It has been shown to be of interest in vascular and cardiac imaging, and to reduce artefacts in bone imaging. However, its performance in oncology analysis has been little studied. The selection of patients for peritoneal and hepatic carcinosis surgery is fundamental, as surgery allows a prolongation of survival, but are associated with a non-negligible morbi-mortality rate.

Spectral CT provides improved detection of peritoneal carcinosis and liver metastases of colorectal cancer compared to conventional CT acquisition.

Conditions

Colo-rectal Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patients with Colo-rectal Cancer

Patients with Colo-rectal Cancer will be included.

CT Images

Intervention Type: OTHER

Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer

Interventions

CT Images

Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis
• Patients with a curative surgical resection plan

Exclusion Criteria

• Patients with non-metastatic colorectal cancer
• Patients treated with chemotherapy without surgical plans
• Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rémi GRANGE, MD

Role: PRINCIPAL_INVESTIGATOR

CHU SAINT-ETIENNE

Locations

CHU Saint-Etienne

Saint-Etienne, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Rémi GRANGE, MD

Role: CONTACT

remi.grange@chu-st-etienne.fr

(0)477828963 ext. +33

Sylvain GRANGE, MD

Role: CONTACT

sylvain.grange@chu-st-etienne.fr

(0)477829066 ext. +33

Facility Contacts

Rémi GRANGE, MD

Role: primary

remi.grange@chu-st-etienne.fr

(0)477828963 ext. +33

Sylvain GRANGE, MD

Role: backup

sylvain.grange@chu-st-etienne.fr

(0)477829066 ext. +33

Other Identifiers

IRBN1162022/CHUSTE

Identifier Type: -

Identifier Source: org_study_id